PDS Biotechnology (PDSB) Accumulated Expenses (2014 - 2026)

PDS Biotechnology (PDSB) has 12 years of Accumulated Expenses data on file, last reported at $271742.0 in Q4 2025.

• Quarterly Accumulated Expenses rose 7.7% year-over-year to $271742.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $271742.0 (up 7.7% YoY) and the FY2025 annual result came in at $271742.0, up 7.7% from the prior year.
• Accumulated Expenses declined to $271742.0 in Q4 2025, from $2.8 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $3.4 million in Q2 2023 to a low of $252322.0 in Q4 2024.
• A 5-year average of $1.5 million and a median of $1.9 million in 2021 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Accumulated Expenses sank 89.59% — and 2025, when it soared 827.89%.
• Tracing PDSB's Accumulated Expenses over 5 years: stood at $1.5 million in 2021, then tumbled by 80.77% to $280382.0 in 2022, then jumped by 764.78% to $2.4 million in 2023, then slumped by 89.59% to $252322.0 in 2024, then advanced by 7.7% to $271742.0 in 2025.
• The last three Accumulated Expenses figures came in at $271742.0 (Q4 2025), $2.8 million (Q1 2025), and $252322.0 (Q4 2024), per Business Quant data.